Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 197, Issue 5, Pages 644-652
Publisher
American Thoracic Society
Online
2017-11-04
DOI
10.1164/rccm.201709-1845oc
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interstitial lung disease points to consider for clinical trials in systemic sclerosis
- (2017) Dinesh Khanna et al. RHEUMATOLOGY
- Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force
- (2017) John H. Powers et al. VALUE IN HEALTH
- Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment
- (2016) Hyun J Kim et al. ANNALS OF THE RHEUMATIC DISEASES
- An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
- (2016) D. Khanna et al. JOURNAL OF RHEUMATOLOGY
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
- (2016) Donald P Tashkin et al. Lancet Respiratory Medicine
- Reliability, validity and responsiveness to change of the Saint George’s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis
- (2015) Beth Wallace et al. RHEUMATOLOGY
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers and surrogate endpoints in clinical trials
- (2012) Thomas R. Fleming et al. STATISTICS IN MEDICINE
- Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis
- (2011) Roland M. du Bois et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease
- (2011) Dinesh Khanna et al. ARTHRITIS AND RHEUMATISM
- Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
- (2011) Carmen Pilar Simeón-Aznar et al. CLINICAL RHEUMATOLOGY
- Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide
- (2011) Hyun J. Kim et al. EUROPEAN RADIOLOGY
- The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF
- (2009) Jeffrey J. Swigris et al. RESPIRATORY MEDICINE
- Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study
- (2009) D. Khanna et al. RHEUMATOLOGY
- The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference
- (2009) J. J. Swigris et al. THORAX
- Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
- (2007) Dennis Revicki et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started